A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5813 participants.
Also called NCT01989754
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,813 participants
- Registry
-
NCT01989754 -
2013-003050-25
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Russia, South Korea, Spain, Sweden, Taiwan, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01989754. Randomized; quadruple masking; primary purpose treatment. Start 2014-01-16 (actual); primary completion 2017-02-23 (actual). Results posted on 2018-12-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
- Acronym
- CANVAS-R
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Albuminuria
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Canagliflozin, 100 mg
- Intervention (Drug)
- Canagliflozin, 300 mg
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- The George Institute for Global Health, Australia
Record details
- Record id
cardio:ct-nct01989754- Content hash
06b66e9e795bc702c4ca10f61ef64baee2a21fd2c603ac394b378248b6207e0a